Recently, we developed a new T-type calcium channel enhancer ethyl-8′-methyl-2′,4-dioxo-2-(piperidin-1-yl)-2′H-spiro[cyclopentane-1,3′-imidazo[1,2-a]pyridin]-2-ene-3-carboxylate (SAK3) (Figure 1), which potentiates Cav3.1 and Cav3.3 currents and revealed its therapeutic effects against AD pathology in AppNL-F/NL-F knock-in (NL-F) mice [17]. Here, CACNA1G is linked to Alzheimer disease.